IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
13 mai 2024 09h00 HE
|
Imunon, Inc.
Proof-of-concept study for Imunon’s first vaccine utilizing its proprietary PlaCCine platform is now open for enrollment Topline results expected this year LAWRENCEVILLE, N.J., May 13, 2024 ...
Imunon to Hold Third Quarter 2022 Financial Results and Business Update Conference Call on Monday, November 14, 2022
07 nov. 2022 08h30 HE
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on DNA-mediated immunotherapy and next-generation vaccines,...
Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting
11 nov. 2019 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Median ACR CRISS score remains 0.95 at 25 months in systemic sclerosis OLE Improvement in CDASI activity score reaches -20.9 points at 23 months in dermatomyositis OLE Favorable safety profile...
ConSynance Presents CSTI-100 Data at NASH Conference
27 sept. 2018 09h00 HE
|
ConSynance Therapeutics, Inc.
Rensselaer, New York., Sept. 27, 2018 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc. announced today that Peter Guzzo, Ph.D., CEO, gave an oral presentation regarding the company's Phase I...